cxc chemokine receptor 2 antagonist azd5069
cxc chemokine receptor 2 antagonist azd5069: 1 clinical trial tracked.
cxc chemokine receptor 2 antagonist azd5069 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
What is verified about cxc chemokine receptor 2 antagonist azd5069, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Primary endpoint: Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansion